Reliant aims for $95m from public listing
This article was originally published in Clinica
Laser systems developer Reliant Technologies announced on August 16 that it is targeting funding of $95m from an initial public offering. The company will offer around 30 million shares at a price of $3.83 per share, in a bid to fund development of its Fraxel family of laser devices used for treating various skin conditions and surgical scars.
You may also be interested in...
A randomized COVID-19 study spanning the whole of the UK could help to bolster the UK’s reputation as a location for future clinical trials. It is also being seen partly as the result of the UK regulator's "decisive action" in fast-tracking trials for potential COVID-19 therapies.
Manufacturers of endoscopic equipment, biofeedback devices and thermometers were among those cited for regulatory violations in US FDA warning letters this week. A total of four device-related enforcement missives were released by the agency.
The biopharma industry has struggled to recruit patients into clinical trials that adequately reflect the diverse patient populations they hope to reach with new products. Failure to improve minority subgroup participation now will cost trial sponsors later.